Skip to main content

ProPhase Labs, Inc.

PRPH
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0000868278

No open-market purchases or sales by ProPhase Labs, Inc. insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $2 in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding ProPhase Labs, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of PRPH: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders2125+4
Shares1.65M1.51M−137.3K (−8.3%)
Value$8.56M$10.8M+$2.26M (+26.4%)

New holders (10)

Institutions that held ProPhase Labs, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to PRPH in Q4 2021
InstitutionSharesValue% of portfolio
Ameriprise Financial Inc134,651$964.0K0.00%
Group One Trading, L.P.3,400$24.0K0.00%
UBS Group AG1,868$13.0K0.00%
Simplex Trading, LLC1,548$11.0K0.00%
The PNC Financial Services Group, Inc.600$4.00K0.00%
Royal Bank of Canada500$4.00K0.00%
Tower Research Capital LLC (TRC)370$3.00K0.00%
North Star Investment Management Corp.100$1.00K0.00%
CoreCap Advisors, LLC100$1.00K0.00%
Dixon Hughes Goodman Wealth Advisors LLC175$1.00K0.00%

Sold out (6)

Institutions that held ProPhase Labs, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of PRPH in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Bank of Montreal158,587$821.0K
Kamunting Street Capital Management, L.P.98,888$514.0K
Susquehanna International Group, LLP31,487$164.0K
Marshall Wace, LLP22,801$119.0K
HighVista Strategies LLC20,256$105.0K
JPMorgan Chase & Co5,730$30.0K